(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/263132 A1

(51) International Patent Classification:
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/US2021/039137

(22) International Filing Date:
25 June 2021 (25.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/044,740 26 June 2020 (26.06.2020) US
63/214,343 24 June 2021 (24.06.2021) US

(71) Applicant: **APRECIA PHARMACEUTICALS LLC** [US/US]; 10901 Kenwood Road, Blue Ash, OH 45242 (US).

(72) Inventors: **YOO, Jaedeok**; 10901 Kenwood Road, Blue Ash, OH 45242 (US). **PHILLIPS, Aleece M.**; 10901 Kenwood Road, Blue Ash, OH 45242 (US). **BRADBURY, Thomas J.**; 10901 Kenwood Road, Blue Ash, OH 45242 (US). **WEST, Thomas G.**; 10901 Kenwood Road, Blue Ash, OH 45242 (US).

(74) Agent: **NESBITT, Daniel F.**; Hasse & Nesbitt LLC, 8837 Chapel Square Drive, Suite C, Cincinnati, OH 45249 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with amended claims and statement (Art. 19(1))*

(54) Title: RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY

(57) Abstract: A rapidly-orodispersible dosage form comprising a porous, bound-powder matrix and one or more internal cavities is provided, as well as three-dimensional printing methods for making the same. Each internal cavity is configured to contain one or more payloads, particularly pharmaceutical medicaments, while isolating the payloads from the external environment outside of the dosage form. Each payload can be contained within its cavity in its native form without having to be combined with the bound-powder matrix or binding liquid. Dosage forms can disintegrate in water or saliva in less than two minutes, independently of the payload(s) or medicament(s) contained within. The dosage forms can be formed as unitary tablets, or as two-piece tablets comprising a container body and a lidding body that are secured together to isolate the one or more cavities and their payloads inside.




Fig. 1

WO 2021/263132 A1